ALTRUBIO
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discover... y and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.
ALTRUBIO
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2000-06-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.altrubio.com
Total Employee:
11+
Status:
Active
Contact:
(650) 988-9912
Email Addresses:
[email protected]
Total Funding:
327.61 M USD
Technology used in webpage:
Mobile Non Scaleable Content U.S. Server Location CrUX Dataset CrUX Top 10m Amazon Frankfurt Region Laravel
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Synta Pharmaceuticals
Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Advisors List
Current Employees Featured
Founder
Investors List
Soleus Capital
Soleus Capital investment in Series B - AltruBio
RA Capital Management
RA Capital Management investment in Series B - AltruBio
Blackstone Group
Blackstone Group investment in Series B - AltruBio
aMoon Fund
aMoon Fund investment in Series B - AltruBio
Cormorant Asset Management
Cormorant Asset Management investment in Series B - AltruBio
Delos Capital
Delos Capital investment in Series B - AltruBio
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - AltruBio
CAM Capital
CAM Capital investment in Series A - AltruBio
aMoon Fund
aMoon Fund investment in Series A - AltruBio
Biotechnology Value Fund
Biotechnology Value Fund investment in Series A - AltruBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-13 | AltruBio snags a CMO after pivot from oncology to immunology |
| 2021-08-09 | AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer |
Official Site Inspections
http://www.altrubio.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.58 K
Unable to get host informations!!!
More informations about "AltruBio"
AltruBio
CITELINE/In Vivo─Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease. 2025 . 05 . 30. Partnology─Biotech Leader Spotlight Series. 2025 . …See details»
AltruBio Inc. - LinkedIn
AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth …See details»
AltruBio - Crunchbase Company Profile & Funding
AltruBio is focused on developing targeted antibody therapeutics for the …See details»
Altrubio Inc. Company Profile | San Francisco, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Altrubio Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
AltruBio - The Org
AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological …See details»
New name, new board, new focus: AltruBio relaunches with $63M …
Apr 15, 2021 Redwood City, California-based AltruBio has also switched out its board, bringing on former AstraZeneca Chief Medical Officer Sean Bohen, M.D., Ph.D., and other industry …See details»
AltruBio lands up to $225M after shift to immune drug research
May 21, 2024 AltruBio is among the beneficiaries of the investment surge. Since rebranding and bringing in former Bayer and Pfizer executive Judy Chou as CEO, the company has secured …See details»
AltruBio President and CEO Judy Chou Appointed to the …
Nov 1, 2022 AltruBio is a privately held biotechnology company headquartered in San Francisco that is focused on developing novel therapeutics for the treatment of immunological diseases …See details»
AltruBio, Inc. - VentureRadar
AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development …See details»
Developing safer, more durable treatments - altrubio.com
Our Leadership. AltruBio's senior management is built on a team of individuals possessing strong academic and drug development knowledge, high-level managerial experience and scientific …See details»
Immune checkpoint enhancer biotech AltruBio raises $225m
May 22, 2024 The new funding follows a $63 million Series A completed in 2021, and comes as AltruBio is testing its lead candidate – ALTB-268 for ulcerative colitis – in a phase 2a trial …See details»
AltruBio raises $225M for midphase ulcerative colitis program
May 21, 2024 AltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase …See details»
AltruBio snags a CMO after pivot from oncology to immunology
Sep 20, 2021 AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board. Jesse Hall, M.D., arrives from Sublimity …See details»
Judy Chou - President & CEO at AltruBio - The Org
About. With 25 years of experience in drug development and biomanufacturing, Dr. Judy Chou currently is the President, CEO, and Board member of AltruBio.Before joining the company, …See details»
AltruBio
AltruBio’s senior management is built on a team of individuals possessing strong academic knowledge, high-level managerial experience and scientific expertise in a range of fields …See details»
Company Overview - altrubio.com
AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development …See details»
AltruBio Presents New Preclinical Data at FOCIS 2025 …
2 days ago SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company developing novel immune checkpoint …See details»
AltruBio Gathers Funds as Biotechs Aim for Next Blockbuster Anti ...
May 21, 2024 Biotechnology startup AltruBio has secured fresh capital to develop a drug for ulcerative colitis as drugmakers compete to develop the next blockbuster therapy for this and …See details»
Join Us - altrubio.com
AltruBio embraces open-minded thinking in a fun, creative and supportive environment to bring innovation to patients. We strive to be visionary, pioneering, agile, caring and excellent. ...See details»
AltruBio
AltruBio to Participate in the Upcoming Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference. 2024 . 10 . 31 . Drug Target Review─Leveraging …See details»